Binnopharm has become the exclusive representative of the German MEDICE


JSC Binnopharm, a Russian full-cycle pharmaceutical company, owned by AFK Sistema, has signed a licensing agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG, ranked among top 15 German manufacturers of OTC drugs. In accordance with the terms of the agreement, JSC Binnopharm becomes the exclusive representative of the German company and receives the exclusive right to market, distribute and sell across Russia 4 medicinal products – Dorithricin®, Meditonsin®, Medivitan® and Fermed® – holding the top sales positions in their therapeutic areas in international markets.

Signing of this agreement continues the strategy of JSC Binnopharm to expand the product portfolio and to enter the market of OTC drugs. Previously the company participated only in tender sales, and in 2015, with the emergence of full-fledged commercial structure and the staff of medical representatives, Binnopharm entered the commercial segment of the pharmaceutical market with several prescription drugs.

Alexey Chupin, CEO of JSC Binnopharm, “This important event will strengthen our position in the commercial and hospital markets, namely in the sales segment of anti-cold, nephrological and neurological medicinal products. Of course, we are truly proud of the fact that it is Binnopharm that will represent in Russia highly efficient and high-quality medicinal products, which are sales leaders in Europe. We have passed the difficult competitive selection to get these products into our portfolio, and we are grateful to our German partners for their trust.”

Katja Pütter-Amner, MD & Richard Amner, MD, PhD, CEO & managing owners of MEDICE Arzneimittel Pütter GmbH & Co. KG.: “We are very pleased to start a long-term relationship with JSC Binnopharm as we share the same basic values and, as our Russian colleagues, focusing on serving people, on the patient and the quality of medicinal products. The partner selection process aiming at promotion of our products in Russia lasted for almost a year, and the company Binnopharm met all our criteria: patient-oriented thinking, qualified team, paying great attention to detail and planning, as well as strong commitment to the core values of medical ethics and business. We have highly appreciated the successful experience of our colleagues from the business unit Binnopharm in promotion of prescription and OTC drugs. We strongly believe in the success of our products in the Russian market.”